Evidence map›Paper›PMID 34944021›Full record

ArticleCells2021

IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism.

Yasu-Taka Azuma, Takashi Fujita, Takeshi Izawa, Kana Hirota, Kazuhiro Nishiyama, Airi Ikegami, Tomoko Aoyama, Mikihito Ike, Yumi Ushikai, Mitsuru Kuwamura and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. International journal of molecular sciences · 2023
    Article
  9. L-arginine-induced pancreatitis aggravated by inhibiting NaThe Journal of veterinary medical science · 2023
    Article
  10. Knockout of Purinergic P2YInternational journal of molecular sciences · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yasu-Taka AzumaLaboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.ORCID 0000-0002-3515-171X
Takashi FujitaMolecular Toxicology Laboratory, Department of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu 525-8577, Japan.ORCID 0000-0001-7417-3551
Takeshi IzawaLaboratory of Veterinary Pathology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.ORCID 0000-0003-3236-6050
Kana HirotaLaboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.
Kazuhiro NishiyamaLaboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.ORCID 0000-0002-6263-3562
Airi IkegamiMolecular Toxicology Laboratory, Department of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu 525-8577, Japan.
Tomoko AoyamaMolecular Toxicology Laboratory, Department of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu 525-8577, Japan.
Mikihito IkeMolecular Toxicology Laboratory, Department of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu 525-8577, Japan.
Yumi UshikaiLaboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.
Mitsuru KuwamuraLaboratory of Veterinary Pathology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Sciences, Osaka 598-8531, Japan.
Hideki FujiiDepartment of Premier Preventive Medicine, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.
Koichi TsuneyamaDepartment of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan.
Osaka Prefecture University · JPRitsumeikan University · JPOsaka City University · JPTokushima University · JP

Funding

Grant-in-Aid for Scientific Research (C) 18K05978
6 · The paper itself

Abstract

Interleukin (IL)-19, a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by macrophages. Nonalcoholic steatohepatitis (NASH) is a disease that has progressed from nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation and fibrosis. We evaluated the functions of IL-19 in a NAFLD/NASH mouse model using a 60% high fat diet with 0.1% methionine, without choline, and with 2% cholesterol (CDAHFD). Wild-type (WT) and IL-19 gene-deficient (KO) mice were fed a CDAHFD or standard diet for 9 weeks. Liver injury, inflammation, and fibrosis induced by CDAHFD were significantly worse in IL-19 KO mice than in WT mice. IL-6, TNF-α, and TGF-β were significantly higher in IL-19 KO mice than in WT mice. As a mechanism using an in vitro experiment, palmitate-induced triglyceride and cholesterol contents were decreased by the addition of IL-19 in HepG2 cells. Furthermore, addition of IL-19 decreased the expression of fatty acid synthesis-related enzymes and increased ATP content in HepG2 cells. The action of IL-19 in vitro suppressed lipid metabolism. In conclusion, IL-19 may play an important role in the development of steatosis and fibrosis by directly regulating liver metabolism and may be a potential target for the treatment of liver diseases.

Indexed as

Adenosine TriphosphateAnimalsCholesterolDiet, High-FatDisease Models, AnimalFatty AcidsHep G2 CellsHumansInflammationInterleukin-6InterleukinsLipid MetabolismLiverMiceMice, KnockoutNon-alcoholic Fatty Liver DiseaseAdenosine TriphosphateCholesterolFatty AcidsIl19 protein, mouseInterleukin-6InterleukinsPalmitatesTransforming Growth Factor betaTriglyceridesTumor Necrosis Factor-alphaIL-19inflammationlipogenesisliverNAFLDNASH

Identifiers

PMID34944021
PMCPMC8699936
OpenAlexW4200024823

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.